GET IT RiGHT: Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

Phase 2, open-label trial of estradiol in gender dysphoria (GD) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Geometric Ratio of Antiretroviral Treatment (ART) Analytes Bictegravir (BIC), Dolutegravir (DTG), and Darunavir (DRV) Trough Concentrations (Ctrough) in Plasma at Each Received Dose of Oral 17-β… at 48 weeks, Percentage of Participants With ART Analyte Trough Concentration (Ctrough) Above Drug-specific Threshold at 48 weeks and 1 more. Started Jan 2024; status: terminated.